Introduction
============

αβ T lymphocytes are activated by the engagement of their antigen receptors (TCR) with peptide/MHC complexes (pMHC) displayed on the surface of antigen presenting cells (APC). An apparent paradox in T lymphocyte biology is that the binding of a TCR with pMHC complexes displayed on the surface of APC has low affinity and a fast off-rate, yet allows the TCR to remain highly sensitive and specific to a particular antigen. How T cells decipher and amplify the information collected on the surface of APC and translate it into versatile biological responses is a central question in T cell biology.

The TCR serial engagement model was proposed as a stepping stone to address this unresolved question (Valitutti et al., [@B52]). A drawback of this model is that it is not based on direct visualization of TCR dynamics at the T cell/APC contact site, but on an estimate of TCR/pMHC binding that uses TCR down-regulation as a parameter of TCR occupancy (Valitutti et al., [@B50]). As discussed below, this approach has been challenged. Moreover measurements of the TCR/pMHC binding parameters in solution provided results that were difficult to reconcile with the possibility that TCR might be rapidly and serially engaged by cell-bound pMHC (Stone et al., [@B44]). Collectively, these observations cast doubts on the idea that serial TCR engagement might actually contribute to the high level of sensitivity characteristic of T lymphocyte responses. Nevertheless, recent studies in which two-dimensional (2-D) binding parameters of TCR interaction with pMHC were considered, provided data in support of the idea that TCR/pMHC binding might be sequential, thus reopening the discussion on whether serial TCR engagement might take place at the T cell/APC contact site (Huang et al., [@B21]; He and Bongrand, [@B19]; Robert et al., [@B40]).

Here I discuss the development of the model and position the old serial engagement hypothesis in the context of what we currently know about T lymphocyte activation. Finally, I discuss how the concept of TCR serial engagement might be helpful in the design of therapies based on adoptive transfer of T cells carrying engineered tumor-specific TCR.

The Serial TCR Engagement Model from an Historical Perspective
==============================================================

When the serial engagement model was proposed T lymphocyte activation was viewed as a paradox. Biochemical studies aimed at defining the minimum number of specific pMHC required to trigger T lymphocyte activation revealed that T cells could proliferate and produce cytokines in response to APC displaying as few as 50--100 specific pMHC complexes among a large number of structurally similar non-stimulatory pMHC (Demotz et al., [@B8]; Harding and Unanue, [@B18]). In addition, cytotoxic T cells (CTL) were reportedly able to kill target cells that were estimated to express as few as 1--10 specific pMHC (Sykulev et al., [@B45]). In spite of the high sensitivity of antigen recognition, the affinity of binding between TCR and pMHC appeared to be much lower than those measured for antibodies. Using different recombinant TCR and pMHC, the affinity of TCR/pMHC interaction in solution was estimated to range between 10−4 and 10−7 M with half-lives of seconds (Matsui et al., [@B34], [@B35]; Corr et al., [@B6]). A complication to the high sensitivity/low affinity conundrum of T cell responses was the notion that T cell activation required sustained signaling, and needed to last for at least a few hours in order to promote cytokine secretion (Weiss et al., [@B55]; Goldsmith and Weiss, [@B13]; Gray et al., [@B17]).

During the last 15 years, the development of high-resolution imaging techniques moved the focus of investigation from the measurement of functional and phenotypic parameters in cell populations to the visualization of molecular dynamics in individual cells at the level of the immunological synapse (IS, Monks et al., [@B36]; Grakoui et al., [@B16]). Recent studies clearly illustrate the high sensitivity of individual T cells to antigenic stimulation, as well as the importance of sustained signaling for T cell activation. In one such study, work by M.M. Davis and colleagues, showed that murine CD4^+^ T cells undergo sustained \[Ca^2+^\]~i~ increase when interacting with APC that display as few as 10--15 specific pMHC at the IS, demonstrating that sustained signaling is actually triggered by a few antigen specific ligands (Irvine et al., [@B25]). Sustained activation of signaling pathways in T cells (including Ca^2+^-calcineurin pathway, PI3K pathway, and PKCθ pathway, etc.) has been mechanistically linked to the nuclear translocation of transcription factors required for cytokine production and proliferation (Timmerman et al., [@B48]; Fabre et al., [@B11]; Zanin-Zhorov et al., [@B58]). Moreover, it has also been shown that, not only the duration of signaling, but also the intensity and the frequency of signal oscillations are important factors that modulate the outcome of T cell responses (Dolmetsch et al., [@B9]; Utzny et al., [@B49]).

About 17 years ago, we observed that when TCR/pMHC interactions in pre-formed conjugates of T cells and APC were blocked by the addition of anti-MHC Class II antibodies, \[Ca^2+^\]~i~ increases ceased within a few minutes and T cells failed to produce IFN-γ (Valitutti et al., [@B51]). This finding suggested that sustained signaling resulted from the prolonged and uninterrupted engagement of TCR with pMHC displayed on the APC surface. A functional actin cytoskeleton appeared to be instrumental for this process by allowing T cells to scan the APC surface and to form areas of tight adhesion with the opposing cell membrane (Valitutti et al., [@B51]). These observations, particularly evident at low antigenic densities, raised the question of how TCR could remain bound to the same few pMHC for long enough to achieve sustained signaling within dynamic T cell/APC contacts.

To determine the number of TCR triggered by pMHC, we measured TCR down-regulation (i.e., the reduction of TCR expression on the cell surface due to internalization and targeting to lysosomes (Valitutti et al., [@B54]), and compared it to immuno-precipitation of iodinated peptides bound to MHC molecules. We calculated that, in T cells interacting with APC displaying low antigenic pMHC densities (∼100 pMHC per APC), a large number of TCR were triggered (up to 18,000 per T cell; Valitutti et al., [@B52]). The above estimates, together with the observation that sustained signaling in T cells required uninterrupted TCR engagement inspired the serial engagement model (Valitutti et al., [@B52]; Valitutti and Lanzavecchia, [@B53]).

According to the model, during a dynamic T cell/APC interaction an increasing number of TCR are engaged and triggered by a small number of specific pMHC displayed on the APC surface resulting in sustained signaling. Such a process is compatible with the short half-lives of TCR/pMHC binding which have been observed in other studies (Figure [1](#F1){ref-type="fig"}).

![**The serial TCR engagement model**. At the IS, a few specific pMHC (red) sequentially trigger incoming TCR resulting in sustained signaling. Triggered TCR are internalized and targeted to lysosomes for degradation while unbound pMHC bind new TCR.](fimmu-03-00272-g001){#F1}

The use of TCR down-regulation as a measure of TCR occupancy has been debated. It has been reported that in dual-TCR-expressing T cells a substantial fraction of non-engaged TCR could be co-modulated in a bystander fashion (San Jose et al., [@B41]). As discussed elsewhere (Valitutti et al., [@B50]), the various studies addressing bystander TCR co-modulation are contradictory. Moreover, the extent to which co-modulation is observed appears to be related to the type of cells used in the different studies. For example, co-modulation is often reported as a phenomenon in Jurkat T cells, but is rarely seen (or reported to be limited) in studies with human T cell clones or mouse primary cells (Valitutti et al., [@B52]; Niedergang et al., [@B37]; San Jose et al., [@B41]; Schrum and Turka, [@B43]; Bonefeld et al., [@B3]; Gladow et al., [@B12]). Why differences among cell systems exist is presently unclear. It is likely that the extent of detectable TCR co-modulation may depend on various cellular parameters, including the fraction of monomeric versus pre-aggregated TCR present on the surface of different T cells. This issue is still debated. One study reported that TCR/CD3 complexes are expressed on the T cell surface essentially as monomers (James et al., [@B27]), while others reported that TCR are, in part, pre-aggregated forming nano-clusters (Schamel et al., [@B42]; Lillemeier et al., [@B32]). Discrepancies among these studies might be due to the different experimental approaches used to determine TCR clustering. Further research is required to address this key point.

In conclusion, in its original formulation the serial engagement model offered a plausible explanation to the low affinity/high sensitivity paradox of T cell activation and suggested a mechanism for the induction of sustained signaling by a few antigenic ligands. However, the original idea of comparing the number of pMHC with the number of down-regulated TCR is *per se* a limitation of the model. Serial TCR engagement needs to be further assessed with modern and more direct experimental approaches.

3-D Versus 2-D TCR/pMHC Interactions
====================================

The serial engagement model predicts that there is a defined window of half-lives of TCR-pMHC binding required for optimal T cell activation (Valitutti and Lanzavecchia, [@B53]). While short half-lives (with rapid TCR/pMHC binding off-rates) prevent productive TCR triggering, as stated by the kinetics-proofreading model (Rabinowitz et al., [@B39]), long half-lives (with slow binding off-rates) reduce the efficiency of TCR serial engagement (Figure [2](#F2){ref-type="fig"}A). However, measurements of TCR/pMHC binding parameters in solution (defined as three-dimensional or 3-D parameters) using surface plasmon resonance (SPR) or comparing the binding of different pMHC tetramers to T cells, provided results that were inconsistent with the optimal half-life hypothesis. While this hypothesis is supported by computational studies (Wofsy et al., [@B56]; Coombs et al., [@B5]) and by some experimental results (Hudrisier et al., [@B22]; Kalergis et al., [@B28]; Cemerski et al., [@B4]; Adams et al., [@B1]), other studies failed to provide evidence for an optimal half-life window (Holler et al., [@B20]; Tian et al., [@B47]). It is possible that some of the discrepancies arise from the different readouts used to monitor T cell activation in the different studies (Corse et al., [@B7]). Recent work has been able to reconcile these apparently contrasting results by showing that, depending on the on-rate of binding, the potency of some pMHC ligands for stimulating T cells correlates better with pMHC/TCR affinity, while the stimulation potency of others is determined instead by an optimal half-life (Aleksic et al., [@B2]; Govern et al., [@B15]). It is important to note that, SPR and tetramer measurements, although useful to compare different TCR ligands, rely on parameters that are estimated from 3-D binding, a condition that might not accurately mimic the situation within the confines of a T cell/APC IS.

![**(A)** The serial engagement model postulates that pMHC ligands exhibiting optimal binding half-lives to TCR behave as optimal agonists; **(B)** At high pMHC densities, pMHC exhibiting long binding half-lives are stimulatory; **(C)** At low pMHC densities, pMHC exhibiting long binding half-lives fail to trigger T cell responses.](fimmu-03-00272-g002){#F2}

Recent technological breakthroughs have made it possible to measure TCR/pMHC binding using experimental approaches that more accurately mimic the 2-D TCR/pMHC interaction within the IS (He and Bongrand, [@B19]).

Huppa et al. investigated the interaction between TCR labeled with fluorescent antibody and expressed on the cell surface, with pMHC embedded in supported lipid bilayers using fluorescence resonance energy transfer (FRET). This analysis showed that in 2-D the on-rate of binding between TCR and pMHC is much faster than that measured in 3-D, and that the dissociation rate of TCR/pMHC bonds in 2-D is 4- to 12-fold more rapid than the rate measured in 3-D. Interestingly, when T cell actin cytoskeleton is poisoned, the differences between 3-D and 2-D off-rates are abolished, indicating that the accelerated off-rates observed in 2-D depend on active cellular dynamics. The study also showed that the 2-D binding affinity is high and correlates with ligand potency, in agreement with previous SPR measurements (Huppa et al., [@B23]).

Huang at al. used micropipettes to immobilize T cells and to form contacts with either red blood cells or beads coated with pMHC to estimated the 2-D on/off-rates of binding by monitoring either red blood cell deformation or thermal fluctuation in the TCR/pMHC binding. This approach reports very fast 2-D on-rates. Surprisingly, off-rates of binding were also found to be extremely rapid (∼8,000 times faster than those measured in solution) and are faster for agonist pMHC ligands than for weak ligands, suggesting serial TCR engagement (Huang et al., [@B21]). The importance of considering both 3-D and 2-D binding kinetics is emphasized by a recent study by K. C. Garcia and colleagues. They show that TCR/pMHC binding parameters are different if measured in solution (in the absence of physical constraints) or in 2-D (Adams et al., [@B1]).

Finally, in a recent and detailed study, Robert et al. used TCR coated microbeads in laminar flow chambers and measured their interaction with surface-immobilized pMHC under cell free conditions (Pierres et al., [@B38]; Robert et al., [@B40]). This analysis showed that 2-D dissociation rates are comparable to 3-D dissociation rates when measured in a cell free system such as this, supporting the idea that accelerated 2-D dissociations of TCR/pMHC bonds found in other studies (Huang et al., [@B21]; Huppa et al., [@B23]), result from active cellular dynamics. Robert et al. ([@B40]) also found that T cell activation increases with a longer binding half-life, but negatively correlates with bond mechanical strength. As discussed below, these results reconcile SPR measurements (reporting that ligand potency increases with binding half-life, Holler et al., [@B20]; Tian et al., [@B47]) with the requirement of rapid bond disruption and re-formation for serial TCR triggering (Valitutti and Lanzavecchia, [@B53]). These observations are also compatible with recent studies showing that TCR can function as mechanosensors (e.g., receptors converting mechanical energy into biochemical signals; Kim et al., [@B30], [@B29]; Li et al., [@B31]; Husson et al., [@B24]; He and Bongrand, [@B19]) and with models of T cell activation postulating that mechanical forces are involved in TCR triggering (Ma and Finkel, [@B33]).

Based on these findings, a current view of T cell activation posits that cytoskeletal movements can fine-tune the half-life of TCR/pMHC interactions in live T cell/APC conjugates. Optimal TCR ligands would have long enough half-lives to trigger receptors but low mechanical strength. Together, these parameters would allow TCR/pMHC bonds to rapidly dissociate and reform within dynamic T cell/APC contacts thus enhancing serial TCR triggering (Ma and Finkel, [@B33]; Robert et al., [@B40]). It is interesting to note that this view goes back to initial observations showing that a functional actin cytoskeleton and T cell motility are instrumental for sustained signaling in T cells triggered by cell-bound ligands (Valitutti et al., [@B51]).

In conclusion, results obtained from 2-D measurements are still too limited and somewhat contradictory to either support or refute the model of serial TCR engagement. Further work, using additional panels of TCR/pMHC pairs and well-standardized 2-D assays, is required to convincingly test the model. However, by showing that binding off-rates can be faster at cellular interfaces due to cytoskeleton-driven dynamics and that bond mechanical strength might influences ligand potency, 2-D methods have re-opened the discussion on the purported relevance of serial TCR engagement.

Could TCR Serial Engagement Be Relevant for Immunotherapy?
==========================================================

The importance of ligand density
--------------------------------

Since its inception, it was implicit that the model of TCR serial engagement would only apply under conditions in which T cells interacted with APC displaying a very small number of antigenic ligands. At high densities of cognate pMHC, TCR serial engagement would be not only difficult to envisage, but also unnecessary. Thus, optimal half-lives of TCR/pMHC binding would be required for serial TCR engagement only at low antigen densities (Figures [2](#F2){ref-type="fig"}B,C).

The first direct evidence supporting this idea came from a study by Gonzales et al. in which the relationship between the density of antigenic ligands and their affinity for TCR was investigated. This study provides computational and experimental data showing that an appropriate TCR/pMHC half-life window is only required to elicit T cell responses at low pMHC densities (Gonzalez et al., [@B14]). Furthermore, Dushek et al. recently emphasized the importance of the strength of antigenic stimulation when comparing "affinity" versus "productive hit rate" models of T cell activation. They employed computational and experimental approaches to correlate solution measurements of TCR/pMHC binding parameters with the potency of a panel of pMHC variants. They reported that dose-responses are better indicators of T cell activation than EC~50~ (half-maximal effective concentration) when relating TCR/pMHC binding affinities to elicited responses (Dushek et al., [@B10]). Direct evidence that serial TCR engagement is dispensable in conditions in which a strong stimulation is provided to T cells also comes from recent findings showing that, when a substantial fraction of TCR is cross-linked with monovalent pMHC embedded in supported lipid bilayers, T cell activation is sustained and amplified (Xie et al., [@B57]).

Requirement for an optimal affinity window in clinically oriented studies
-------------------------------------------------------------------------

Understanding whether or not TCR exhibiting an intermediate affinity might efficiently trigger T cell activation at low antigen densities, is relevant for cancer immunotherapies that are based on adoptive T cell transfer. In contrast to infectious diseases, malignant neoplastic diseases are characterized as having relatively slow progression and displaying low antigen densities. A study in which the functional properties of T cells transduced with TCR exhibiting various binding affinities were compared *in vitro*, reported that human T cells transduced with TCR of intermediate affinity are sensitive to low antigenic stimuli and do not exhibit cross-reactivity (Zhao et al., [@B59]). Recent clinically oriented studies further illustrate the importance of the balance between the strength of antigenic stimulation and TCR binding properties. Thomas et al. showed that human non-transformed T cells transduced with affinity-matured TCR (specific for a HIV-derived Gag peptide) that exhibit 700-fold increased affinity to its cognate pMHC, require much higher pMHC densities to trigger T cell responses than wild-type TCR (Thomas et al., [@B46]). Irving et al. used a rational design to generate a panel of human TCR specific for a tumor antigen peptide and that exhibited a variety of affinity/off-rates (measured in 3-D using SPR). They show that human non-transformed T cells transduced with TCR engineered to have supraphysiologic affinity for pMHC, exhibit defective responses at low/intermediate antigen doses. By increasing antigen dose, the deficiency of high affinity TCR to elicit optimal T cell responses is gradually overcome (Irving et al., [@B26]).

In conclusion, increasing evidence indicates that appropriate TCR/pMHC binding half-lives would, at low antigen densities, potentiate T cell responses. However, on the basis of available data, it is difficult to predict whether TCR ligands with an intermediate affinity might elicit stronger responses *in vivo* and, in turn, substantially improve the outcome of immunotherapies based on T lymphocyte adoptive transfer. It may be important to test this hypothesis in clinics and therefore consider T cell-based therapies using intermediate affinity engineered TCR.

Concluding Remarks
==================

More than 17 years after its proposal the serial TCR engagement model is still avidly debated. Recent observations showing that TCR with intermediate binding half-lives for pMHC can efficiently trigger T cells at low antigen densities, and that TCR/pMHC dissociation rates in 2-D are very rapid suggest that serial TCR engagement events might actually occur within the confines of T cell/APC synapses. However, available data are contradictory. It is unlikely that the serial TCR engagement model will be able to explain results obtained in all the different systems and experimental conditions. Several parameters, such as the strength and quality of antigenic stimuli, the quality of the APC and the context in which antigen presentation takes place, influence T cell responses. The fact that available data have been obtained using different T cell models (such T cell hybridomas, transgenic T cell systems, non-transformed T cells, etc.) does not help clarify our understanding on whether or not, and to what extent, TCR serial engagement might contribute to T cell activation.

In the future it should be possible to address these unresolved issues. For example, the recent development of high-resolution live cell microscopy techniques should allow the visualization of the dynamics of individual TCR/pMHC encounters at the IS by combining single particle tracking with other florescence microscopy techniques. These approaches will allow investigators to "see" under which conditions serial engagement may take place. Furthermore, the necessity of testing panels of T cells carrying engineered tumor-specific TCR for adoptive transfer therapies, will allow systematic and in-depth analysis of 3-D and 2-D TCR/pMHC binding parameters and help to clarify the relationship between different binding parameters and stimulation potency.

It is intriguing that these clinically oriented studies are bringing back the idea of serial TCR engagement to the experimental system in which it was originally conceived: human non-transformed T cells. The actual relevance of serial TCR engagement in the process of T cell activation in different T cell systems is still elusive and may well be limited. Nevertheless, it would be an excellent outcome for this model if it can contribute, at least to a certain extent, to the design of immunological strategies to fight cancer.
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